We are TAE Life Sciences

TAE Life Sciences (TLS) is a biologically-targeted radiation therapy company focused on developing novel treatments to improve the lives of patients with invasive, recurrent and difficult to treat cancers.


A Total Solution

Founded in 2017, TLS is the only company developing comprehensive target drugs and neutron technology product portfolio to enable next-generation boron neutron capture therapy (BNCT) as a first-line treatment for patients globally.

The company has made a significant investment in developing a portfolio of new Boron-10 target drugs, with the goal of expanding the application of BNCT to new cancer types and to provide even better outcomes for indications historically treated with Boronophenylalanine (BPA), the only target drug currently utilized in BNCT.

Leadership Team


Bruce Bauer, PhD

Chief Executive Officer

Robert Hill

Chief Operating Officer

Kendall Morrison, PhD

Chief Science Officer

Anna Theriault

Global Vice President Marketing and Strategy

Chad Lee, PhD

Director of Clinical Development

Arnold Dijkstra

Vice President of Business Development, EMEA

Board of Directors


Bruce Bauer, PhD

Chief Executive Officer, TAE Life Sciences

Michl Binderbauer, PhD

Chief Executive Officer, TAE Technologies, Inc.

Stuart Peterson

Co-Founder and President, ARTIS Ventures

Artem Smirnov, PhD

Chief Technology Officer, TAE Technologies, Inc.

Clinical Advisory Board

Richard Amos, PhD

University College London, UK

Garth Cruickshank, MD, PhD

Emeritus Professor of Neurosurgery, University of Birmingham UK

Daniel Low, PhD

University of California, Los Angeles

Vivek Mehta, MD

Swedish Cancer Institute

Jack Phan, MD, PhD

UT MD Anderson Cancer Center

James Welsh, MD

Loyola University, Edward Hines JR VA Hospital


Join the team committed to revolutionizing cancer treatment. TAE Life Sciences is currently hiring for the following positions:

Apply Today!